These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 5327466)

  • 1. Withdrawal of ataractic medication in schizophrenic patients.
    Garfield SL; Gershon S; Sletten I; Neubauer H; Ferrel E
    Dis Nerv Syst; 1966 May; 27(5):321-5. PubMed ID: 5327466
    [No Abstract]   [Full Text] [Related]  

  • 2. Piperacetazine in ambulatory chronic schizophrenic patients.
    Rada RT; Donlon PT
    Curr Ther Res Clin Exp; 1974 Feb; 16(2):124-9. PubMed ID: 4156665
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlled study of BL-KR140 on chronic anergic schizophrenic patients stabilized with a neuroleptic compound.
    Dim BH; Kurland AA
    Curr Ther Res Clin Exp; 1968 Jun; 10(6):288-91. PubMed ID: 4969835
    [No Abstract]   [Full Text] [Related]  

  • 4. The effectiveness of combined phenothiazine and butyrophenone treatment in chronic schizophrenic patients.
    Lehmann HE; Ban TA; Lee H
    Curr Ther Res Clin Exp; 1967 Jan; 9(1):36-7. PubMed ID: 4963021
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of Tybamate in chronic schizophrenia. (Minor tranquilizers as adjunct therapy in psychosis).
    Serafetinides EA; Clark ML
    Dis Nerv Syst; 1971 Aug; 32(8):567-71. PubMed ID: 5094163
    [No Abstract]   [Full Text] [Related]  

  • 6. An uncontrolled clinical study with piperacetazine in the maintenance treatment of chronic schizophrenic patients.
    Amin MM; Brahm E; Ban TA; Lehmann HE
    Psychopharmacol Bull; 1977 Jul; 13(3):10-1. PubMed ID: 18753
    [No Abstract]   [Full Text] [Related]  

  • 7. [Time relationship between the appearance of persisting extrapyramidal hyperkineses and psychotic recurrences following sudden interruption of prolonged neuroleptic therapy of chronic schizophrenic patients].
    Degkwitz R; Bauer MP; Gruber M; Hampel G; Luxenburger O; Richartz M; Wenzel W
    Arzneimittelforschung; 1970 Jul; 20(7):890-3. PubMed ID: 4918918
    [No Abstract]   [Full Text] [Related]  

  • 8. A controlled study of the effects of gamfexine in phenothiazine-treated patients.
    Zimmermann RL; Vestre ND; Schiele BC; Curran J
    Curr Ther Res Clin Exp; 1970 Apr; 12(4):230-3. PubMed ID: 4985944
    [No Abstract]   [Full Text] [Related]  

  • 9. Piperacetazine (Quide): a controlled evaluation of the elixir in chronic schizophrenic patients.
    Gallant DM; Bishop MP
    Curr Ther Res Clin Exp; 1970 Jun; 12(6):387-9. PubMed ID: 4987346
    [No Abstract]   [Full Text] [Related]  

  • 10. One-year study of fluphenazine enanthate.
    Hsu JJ; Nol E; Martinez ML; Lessien B; Paragas PG; Puhac M; Braun RA
    Dis Nerv Syst; 1967 Dec; 28(12):807-11. PubMed ID: 4864388
    [No Abstract]   [Full Text] [Related]  

  • 11. Carphenazine in the treatment of schizophrenic psychoses. Controlled clinical trial.
    Vinar O; Formánková M; Taussigová D; Růzicka S
    Act Nerv Super (Praha); 1967 Nov; 9(4):353-5. PubMed ID: 4889058
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective drug action related to chronic schizophrenic subtype. (A comparative study of carphenazine, chlorpromazine, and trifluoperazine).
    Platz AR; Klett CJ; Caffey EM
    Dis Nerv Syst; 1967 Sep; 28(9):601-5. PubMed ID: 4861216
    [No Abstract]   [Full Text] [Related]  

  • 13. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses.
    Ballenger JC; Post RM
    Psychopharmacol Bull; 1984; 20(3):572-84. PubMed ID: 6382378
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of hydroxyzine on phenothiazine therapy.
    Ross EK; Priest RG
    Dis Nerv Syst; 1970 Jun; 31(6):412-4. PubMed ID: 4393988
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy.
    Hershon HI; Kennedy PF; McGuire RJ
    Br J Psychiatry; 1972 Jan; 120(554):41-50. PubMed ID: 4557435
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship between the hospital milieu and the response to phenothiazines in the treatment of schizophrenics.
    Klerman GL; Goldberg SG; Davis D
    Acta Psychiatr Belg; 1970 Nov; 70(6):716-29. PubMed ID: 4931261
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinical determination of unique effect of potentiation of phenothiazine medication by nylidrin hydrochloride.
    Chu J; Doering MF; Fogel EJ
    Int J Neuropsychiatry; 1966 Feb; 2(1):53-9. PubMed ID: 5907814
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in clinical effects of three phenothiazines in "acute" schizophrenia.
    Dis Nerv Syst; 1967 Jun; 28(6):369-83. PubMed ID: 5342391
    [No Abstract]   [Full Text] [Related]  

  • 19. Chlordiazepoxide in the treatment of patients with "activated EEG's".
    Monroe RR; Dale R
    Dis Nerv Syst; 1967 Jun; 28(6):390-6. PubMed ID: 5340423
    [No Abstract]   [Full Text] [Related]  

  • 20. A preliminary study of SKF-14,336 in chronic schizophrenia.
    Simpson GM; Iqbal J; Iqbal F
    Curr Ther Res Clin Exp; 1966 Sep; 8(9):447-51. PubMed ID: 4957931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.